Photobiological regulation therapeutic instrument for treating open-angle glaucoma and using method

Abstract

The invention discloses a photobiological regulation therapeutic instrument for treating open-angle glaucoma and a using method. According to the photobiological regulation therapeutic instrument, near-infrared light with a wavelength of 600-800 nm relative to light-emitting viewpoints of a left eye sight glass and a right eye sight glass is set to activate photoreceptors in eye cells of a glaucoma patient, promote light energy to be converted into metabolic energy, reduce intraocular pressure of a glaucoma patient, and provide greater possibility for vision recovery of the patient. On one hand, by irradiating the eyeball-ciliary body, aqueous humor generation is reduced, aqueous humor backflow is promoted, intraocular pressure is reduced, on the other hand, glaucoma optic nerve damage can be reduced and injured optic nerve repair can be promoted through low-dose red light irradiation, and in addition, neurons of optic nerves need high-energy mitochondria ATP to meet tissue requirements, and are very sensitive to glucose consumption or energy deficiency, oxidative stress, and mitochondrial dysfunction. Near-infrared light can promote mitochondrial injury repair and improve mitochondrial functions, and has important application value in optic nerve injury treatment.

Description

technical field [0001] The invention relates to a treatment device for primary open-angle glaucoma, in particular to a photobiomodulation therapeutic instrument for treating open-angle glaucoma and a method of use thereof. Background technique [0002] Primary open-angle glaucoma (POAG) is a chronic degenerative disease often associated with elevated intraocular pressure, characteristic depression of the optic disc, and typical visual field defects. Irreversible functional and anatomical changes are seen as a direct consequence of different risk factors, especially elevated IOP. In the 40-year-old population, the prevalence of POAG is 2%. It is estimated that more than 70 million people are affected worldwide. Current treatment options for POAG include topical medications and surgical procedures aimed at reducing IOP to a presumed personal target value. While these treatments may slow the progression of glaucoma, they cannot prevent irreversible vision loss. As a result,...

AI Technical Summary

Problems solved by technology

Since the clinical application of new technologies in my country is still in its infancy, clinical exploration with large samples and randomized controlled trials is needed in the future to explore the factors for the success or failure of each operation. pressure, relieve the speed of optic nerve atrophy, but cannot protect the optic nerve, let alone reverse the optic nerve damage

Images